Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-10-27Clinical Trial Update: A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. [Phase 3]
Phase 3 trial evaluating the combination of daclatasvir and sofosbuvir for HIV and hepatitis C coinfection; the study has completed and resu…
-
CLINICAL_TRIALS trial_result · 2015-10-23Clinical Trial Update: Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care [Phase 2]
A Phase 2 study by Bristol-Myers Squibb evaluating an antiviral combination therapy for chronic hepatitis C in patients who had not received…
-
CLINICAL_TRIALS trial_result · 2015-10-23Clinical Trial Update: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients [Phase 2]
A Phase 2 trial evaluating the addition of daclatasvir to standard of care in treatment-naïve hepatitis C patients. The study is completed a…
-
CLINICAL_TRIALS trial_result · 2015-10-23Clinical Trial Update: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) [Phase 2]
A Phase 2 trial evaluated daclatasvir (BMS-790052) in combination with standard of care for hepatitis C; the study completed and results wer…
-
CLINICAL_TRIALS trial_result · 2015-10-20Clinical Trial Update: Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant [Phase 3]
Phase III trial update evaluating daclatasvir + sofosbuvir + ribavirin in cirrhotic Hepatitis C patients and those post-liver transplant. Re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-10-20Clinical Trial Update: "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study" [Phase 4]
A Phase 4 pilot study completed that evaluated the pharmacoeconomic aspects of autophagy inhibition in hepatitis C patients resistant to sta…
-
CLINICAL_TRIALS trial_result · 2015-10-19Clinical Trial Update: Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients [Phase 3]
Phase 3 clinical trial evaluating asunaprevir and daclatasvir on immune status in chronic hepatitis C patients has completed, with an update…
-
CLINICAL_TRIALS trial_result · 2015-10-15Clinical Trial Update: An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes [NA]
This completed clinical trial evaluates an integrated care model to improve outcomes for patients with Hepatitis C. Results have been posted…
-
CLINICAL_TRIALS trial_result · 2015-10-14Clinical Trial Update: A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects [Phase 2]
A Phase 2 multiple ascending-dose study of daclatasvir (BMS-790052) in hepatitis C genotype 1–infected subjects has completed, with results …
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients [Phase 2]
Phase 2 trial evaluating safety and efficacy of daclatasvir (BMS-790052) plus pegylated interferon alfa-2b and ribavirin in Japanese patient…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment [Phase 2]
Phase 2 study of BMS-790052 (daclatasvir) combined with pegylated interferon and ribavirin in patients who failed prior hepatitis C treatmen…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care [Phase 2]
A Phase 2 study sponsored by Bristol-Myers Squibb evaluated an antiviral combination for chronic hepatitis C in patients who previously fail…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects [Phase 3]
A Phase 3 trial comparing asunaprevir plus daclatasvir versus telaprevir in Japanese patients with hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin [Phase 2]
A Phase 2 study evaluated BMS-650032 in combination with peginterferon alfa-2a and ribavirin for hepatitis C. The trial has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject [Phase 2]
A Phase 2 antiviral combination trial in Japanese patients with Hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) [Phase 3]
This document reports the completion of a Phase III trial evaluating a quadruple regimen of asunaprevir, daclatasvir, pegylated interferon, …
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 [Phase 3]
Phase 3 safety and efficacy trial comparing pegylated interferon lambda with and without daclatasvir against pegylated interferon alfa plus …
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis [Phase 3]
Phase 3 UNITY 2 evaluates a fixed-dose DCV+ASV+BMS-791325 regimen (DCV 3DAA) with or without RBV for 12 weeks in chronic hepatitis C genotyp…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin [Phase 2]
Phase 2 safety study evaluating pegylated interferon lambda in combination with one or two direct-acting antivirals plus ribavirin for hepat…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy [Phase 3]
Phase 3 trial evaluating the efficacy and safety of peginterferon lambda-1a plus ribavirin plus daclatasvir in Hepatitis C genotype 1b patie…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin [Phase 2]
Phase 2 safety study evaluating pegylated interferon lambda-1a in combination with one or two direct-acting antiviral agents plus ribavirin …
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients [Phase 3]
Phase 3 trial evaluating BMS-790052 in combination with BMS-650032 in Japanese patients with hepatitis C has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) [Phase 3]
A Phase III study named Hallmark DUAL evaluated the combination of asunaprevir and daclatasvir for Hepatitis C, with the trial status showin…
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects [Phase 1, Phase 2]
This document notes the completion of a single ascending dose study of BMS-791325 in subjects with chronic hepatitis C in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2015-10-09Clinical Trial Update: Ph IIA Study (SOC +/- NS5B) [Phase 2]
Phase IIa study evaluating SOC with or without an NS5B inhibitor for hepatitis C has completed.